Compositions and methods for the treatment of wounds and the reduction of scar formation

• US 7,323,184 B2
• Filed: 06/28/2006
• Issued: 01/29/2008
• Est. Priority Date: 08/22/2005
• Status: Expired due to Fees

• Current Assignee: Osiris Therapeutics Incorporated (Smith & Nephew PLC)
• Original Assignee: Healagenics, Inc.
• Inventors: Freddo, Mary Ellen, Yoo, Naechoon, Yoo, Won Min, Keum, Ki Chang
• Primary Examiner(s): Landau; Sharmila Gollamudi
• Application Number:
  US11/476,543
• Publication Number:
  US 20070059377A1
• Time in Patent Office: 580 Days
• Field of Search: 424/400, 424/422, 424/426, 424/434, 424/520
• US Class Current: 424/400
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to methods and compositions for inhibiting scar formation on wound region. In certain embodiments, the methods include administering an alkalinization agent in combination with hyaluronic acid to a wound site to reduce the formation of scars at the wound site. Suitable alkalization agents include sodium bicarbonate, sodium hydroxide and potassium hydroxide.

Claims

1. A method for reducing scar formation at a wound site comprising administering to the wound site an effective amount of a composition consisting essentially of:

hyaluronic acid, or the sodium salt thereof; and

an alkalinizing agent in an amount sufficient to raise the pH of the wound site, to allow the wound site to heal and thereby reduce scar formation at the site, wherein the composition has an alkaline pH of about 8.5 to 10.

2. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

3. The method of claim 2, wherein the composition is buffered.

4. The method of claim 1, wherein the composition is administered to the wound site by topical administration to the wound.

5. The method of claim 1, wherein the alkalinizing agent is selected from a group consisting of sodium bicarbonate, sodium hydroxide, potassium hydroxide, tromethamine (THAM), acetazolamide (Diamox), sodium citrate, potassium citrate, potassium phosphate, dibasic sodium phosphate, tribasic sodium phosphate, and sodium lactate.

6. The method of claim 1, wherein the alkalinizing agent is sodium bicarbonate, sodium hydroxide, or potassium hydroxide.

7. The method of claim 2, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery, subcutaneous delivery, body cavity delivery or topical delivery.

8. The method of claim 1, wherein the composition is administered to a body cavity of the ear, nose or throat, optionally after surgery.

9. The method of claim 2, wherein the concentration of hyaluronic acid is between 0.5% to 5% (wt./wt.).